Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
NCT07033585Phase 3Active, not recruiting
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin, saxagliptin in type 2 diabetes mellitus (T2DM). Started Jun 2026; status: active, not recruiting.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07033585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033585.